TRML
Tourmaline Bio, Inc. (TRML) 10Y Growth Potential Analysis (2026)
Overall Score
Revenue Growth
No revenue data provided in fresh metrics, so there is no evidence of sustained top-line growth.
Insufficient evidence of durable revenue expansion.
Profitability
TTM margins are all 0 or negative, with return on assets at -17.1% and return on equity at -17.1%.
Current profitability remains deeply negative.
Financial Health
Liquidity is very strong with a current ratio of 24.7 and cash ratio of 3.1.
Leverage is minimal, with debt-to-equity at 0.0006 and debt-to-assets at 0.0005.
Balance sheet strength remains a clear positive.
Cash Flow
Free cash flow is negative, with free cash flow yield at -3.4% and operating cash flow ratio at -4.15.
Operating cash flow per share is -1.63 and free cash flow per share is -1.63.
Cash generation is still negative despite strong liquidity.
Growth Runway
The company has ample liquidity and very low leverage, which supports runway.
However, the absence of positive revenue and earnings data limits confidence in long-term compounding.
Runway is supported by the balance sheet, but operating performance is not yet validating growth.
Valuation
Valuation looks optically inexpensive on cash-flow-based multiples, but those multiples are distorted by negative cash flow.
Price-to-book is 4.77 and book value per share is 10.06.
Valuation is mixed because cheap-looking cash-flow multiples are not supported by positive cash generation.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Tourmaline Bio, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

